Results of mean differences. by Ekkarat Meephu (15307058)

“…A simulation was conducted to identify 20 scenarios in order to discover the optimal scenario in which where the number of requests (stretchers or wheelchairs) was increased, while the number of staff was decreased to determine mean waiting times and confidence intervals. …”

PGRN deletion decreased the susceptibility to invasive <i>C</i>.<i>albicans</i> infection in mice. by Jiayu Liu (3951515)

Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

Subjects:

Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

Subjects:

Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

Subjects:

Spearman correlations between the age of the sample donor (20–70 years) and estimated proportions of neuronal, glial, and endothelial cells. by Arttu Autio-Kimura (20454681)

Subjects:

Trends in the observed total annual rainfall and mean temperature over Taita Taveta (1981–2020). by Francis Kibagendi Nyambariga (16425739)

Subjects:

Bootstrapped spearman correlations from a randomly selected subset of male sample donor originating samples (n = 493). by Arttu Autio-Kimura (20454681)

Subjects:

Intrathecal injection of IGF2 siRNA decreases IGF2 mRNA expression in the spinal cord. by Wei-Hung Chan (11785304)

Predicted banana distribution map (2016) using logistic regression model M2-12 fitted using 12 covariates and significant two-way combinations. by Dennis Ochola (11626912)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: